Thrombolytics for occluded catheters

Critical Care Medicine

Volumn 32, Issue 10, 2004, Pages 2146-2147

  Horne III, McDonald K ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Alteplase; Catheters; Recombinant urokinase; Venous access

Indexed keywords

ALTEPLASE; FIBRIN; FIBRINOLYTIC AGENT; RECOMBINANT UROKINASE; STREPTOKINASE; UNCLASSIFIED DRUG; UROKINASE;

BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; CATHETER; CATHETER OCCLUSION; CENTRAL VENOUS CATHETER; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; FIBRINOLYTIC THERAPY; INDWELLING CATHETER; INFUSION; INTERMETHOD COMPARISON; PATIENT CARE; PRIORITY JOURNAL; SHORT COURSE THERAPY; VASCULAR ACCESS; VASCULAR PATENCY;

CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; EQUIPMENT FAILURE; FIBRINOLYTIC AGENTS; HUMANS; THROMBOSIS;

EID: 5644276284     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000142905.76171.B6     Document Type: Editorial

References (13)

1. Stephens LC, Haire WD, Kotulak GD: Are clinical signs accurate indicators of the cause of central venous catheter occlusion? JPEN J Patenter Enteral Nutr 1995; 19: 75-79
2. Raad II, Luna M, Khalil SAM, et al: The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271:1014-1016
3. Tschirhart JM, Rao MK: Mechanism and management of persistent withdrawal occlusion. Am Surg 1988; 54:326-328
4. Hurtubise MR, Bottino JC, Lawson M, et al: Restoring patency of occluded central venous catheters. Arch Surg 1980; 115:212-213
5. Glynn MFX, Langer B, Jeejeebhoy KN: Therapy for thrombotic occlusion of long-term intravenous alimentation catheters. JPEN J Parenter Enteral Nutr 1980; 4:387-390
6. Monturo CA, Dickerson RN, Mullen JL: Efficacy of thrombolytic therapy for occlusion of long-term catheters. JPEN J Parenter Enteral Nutr 1990; 14:312-314
7. Wachs T: Urokinase administration in pediatric patients with occluded central venous catheters. J Intraven Nurs 1990; 13:100-102
8. Haire WD, Atkinson JB, Stephens LC, et al: Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blinded, randomized trial. Thromb Haemost 1994; 72:543-547
9. Ponec D, Irwin D, Haire WD, et al: Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: A double-blind placebo-controlled trial. The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12:951-955
10. Deitcher SR, Fesen MR, Kiproff PM, et al: Safety and efficacy of alteplase for restoring function in occluded central venous catheters: Results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2001; 20:317-324
11. Shen V, Li X, Murdock M, et al: Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded venous catheters in pediatric patients. J Pediatr Hematol Oncol 2003; 25:38-45
12. Svoboda P, Barton RP, Barbarash OL, et al: Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: A multiple-center, international trial. Crit Care Med 2004; 32:1990-1996
13. Credo RB, Burke SE, Barker WM, et al: Recombinant urokinase (r-UK): Biochemistry, pharmacology, and clinical experience. In: New Therapeutic Agents in Thrombosis and Thrombolysis. Sasahara AA, Loscalzo J (Eds). New York, Marcel Dekker, 1997, pp 513-537